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ImmunogenicityMother-to-child-transmission of HIV by breast-feeding remains a major obstacle in the eradication of HIV
infection. Compared to adults, HIV-infected infants have more rapid disease and show higher susceptibil-
ity to co-infections like tuberculosis (TB). Although the Bacille Calmette–Guérin vaccine can be adminis-
tered at birth to protect against TB, BCG can disseminate in HIV-infected infants and increase mortality.
Thus, a pediatric combination vaccine to stop both HIV and TB infection in infants is urgently needed.
Towards the goal of developing a pediatric combination HIV-TB vaccine to prevent both oral HIV acqui-
sition by breast-feeding and TB infection, we tested and optimized an immunization regimen using a
novel live attenuated Mycobacterium tuberculosis vaccine engineered to express simian immunodeﬁ-
ciency (SIV) antigens followed by heterologous MVA-SIV boosting in the infant macaque model. A single
oral dose of the attenuated Mtb-SIV vaccine strain mc26435 during the ﬁrst week of life was sufﬁcient to
induce persistent TB-speciﬁc immune responses. SIV-speciﬁc immunity was induced at low but compa-
rable magnitudes after oral or intradermal priming, and was enhanced following MVA-SIV boosts. T cell
responses were most pronounced in intestinal tissues and oral lymph nodes. Importantly, in addition to
plasma SIV-speciﬁc IgG and IgA antibodies, infant macaques developed mucosal SIV-speciﬁc IgA in saliva
and intestinal IgA and IgG. While future SIV and Mtb challenge studies will be needed to determine the
protective efﬁcacy of theMtb-SIV/MVA-SIV vaccine, infants at high risk for oral HIV acquisition by breast-
feeding and TB infection could profoundly beneﬁt from an effective combination vaccine.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-SA license. 1. Introduction
The coverage of antiretroviral therapy (ART) for HIV-infected
mothers has increased substantially, yet many resource-poor
countries are still afﬂicted by rising rates of HIV mother-to-child-
transmission (MTCT) [1]. Infant ART coverage remains below 30%
and ART prophylaxis does not span the entire breast-feedingperiod [1]. The majority of pediatric HIV infections occur in sub-
Saharan Africa where tuberculosis (TB) burden is also high. HIV-
infected infants face a higher risk of TB infection [2], and pregnant
women co-infected with HIV and TB are more likely to transmit
both HIV and TB to their infants [2,3]. The Bacille Calmette–Guérin
(BCG) vaccine for prevention of TB infection can disseminate in
HIV-infected infants with a case fatality of 75% [4]. The high mor-
bidity and mortality associated with HIV and TB disease in infants
underscore the urgent need for a safe neonatal vaccine to prevent
pediatric HIV and TB infections.
Currently, BCG is the only live attenuated vaccine approved for
administration in neonates at birth. BCG-inherent adjuvant proper-
ties likely enhance pediatric immune responses because a single
BCG dose induces robust cellular immunity comparable to re-
sponses in adults. These compelling facts provided the rationale
for the development of combination HIV-TB vaccines. In fact, based
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vaccine expressing an African consensus HIV-1 clade A Gag immu-
nogen (rBCG.HIVA) [5–8], phase I clinical trials have been initiated
in African neonates. The restriction of preclinical BCG-HIV immu-
nogenicity and safety studies to murine models or adult macaques
[5,7–12], however, is problematic. Substantial differences in (i) in-
fant and adult immune function, (ii) immune development be-
tween neonatal mice and human newborns, and (iii) inherent
limitations of BCG-derived vaccines (importantly the safety risk
for immunocompromised individuals and lack of relevant protec-
tive TB antigens), argue for the tandem pursuit of alternative
regimens.
We hypothesized that a live attenuated human-adapted
Mycobacterium tuberculosis (Mtb) vaccine similar to BCG but with
an improved safety proﬁle could be safe and protective, even in
immunosuppressed infants. We chose human-adapted Mtb
H37Rv in lieu ofM. bovis-derived BCG becauseMtb contains known
immunodominant epitopes for humans that are absent in BCG
[13,14]. Secondly, we intentionally deleted speciﬁc H37Rv genes
important for replication and immune evasion, whereas BCG was
attenuated only through serial passaging. Rhesus macaques are
an ideal and validated animal model in which to evaluate our com-
bination vaccine due to their extremely sensitivity to Mtb and to
simian immunodeﬁciency virus (SIV) [16–18], and the shared
immunological, developmental and physiological similarities be-
tween human infants and neonatal macaques [19–21]. The transla-
tional potential of our vaccine for application in human infants at
risk for HIV is supported by our data demonstrating that neonatal
SIV-infected macaques could be safely vaccinated with the live
attenuated auxotroph Mtb vaccine mc26435 [15].
Towards the long-term goal of developing a pediatric HIV-TB
vaccine, the current study tested whether this highly attenuated
recombinant Mtb-SIV vaccine can efﬁciently prime both Mtb and
SIV-speciﬁc immunity. To establish proof-of concept, we deemed
the expression of only a single SIV antigen, SIV Gag, by mc26435
sufﬁcient. SIV Gag contains numerous immunogenic T cell epi-
topes, and several vaccine studies support the importance of SIV
Gag-speciﬁc T cell responses in the control of viral replication
[22–24]. Indeed, our data demonstrate that (i) a single dose of
mc26435 induced both Mtb- and SIV-speciﬁc immune responses
in infant macaques, (ii) vaccine-induced SIV immunity was en-
hanced and broadened by heterologous MVA-SIV Gag, Pol and
Env boosts, and (iii) the combined oral Mtb-SIV Gag prime/intra-
muscular MVA-SIV regimen effectively induced mucosal and sys-
temic immune responses.2. Materials and methods
2.1. Animals
Infant rhesus macaques (Macaca mulatta), obtained from the
SIV-negative and type D retrovirus-free CNPRC colony (UC Davis,
CA), were nursery-reared and housed according to the ‘‘Guide for
Care and Use of Laboratory Animals’’ and standards by the AAALAC.
Animal protocols were approved by the UC Davis Institutional Ani-
mal Care and Use Committee. For all interventions, animals were
immobilized by 10 mg/kg body weight of ketamine–HCl (Parke-
Davis, Morris Plains, NC), injected intramuscularly (IM).2.2. Vaccine strains and immunization regimens
The construction, attenuations and safety proﬁles of the Mtb
H37Rv-derived vaccine strains mc26435 and mc26020 have been
described previously [15,25–30]. Brieﬂy, in strain mc26020, the
panCD and lysA loci were deleted to generate a highlyreplication-attenuated double-auxotroph strain. The double-auxo-
troph strain mc26435 (DpanCDDleuCD) was further modiﬁed by
deleting the secA2 locus, and engineered to co-expresses a myco-
bacterial codon-usage-optimized full length SIVmac239 Gag cas-
sette. SIV Gag expression from vaccine cultures was conﬁrmed by
immunoblot using a V5 antibody-HRP.
Infant macaques (n = 8) were orally (PO) vaccinated with
mc26435 at birth (3–7 days old = week 0), IM boosted at 3 and 6
weeks with MVA-SIV expressing SIV Gag, Pol, and Env (kindly pro-
vided Dr. B. Moss and Dr. P. Earl, NIAID, NIH, Bethesda, MD) [31–
33], and followed for 18 weeks (group A). Age-matched control
animals (n = 3) were mock-vaccinated with saline (group B). To
test how replication–attenuation affects Mtb-speciﬁc immune re-
sponses, three infants were vaccinated both PO and intradermally
(ID) with strain mc26020 without boosting, and followed for 24
weeks (group C).
2.3. Sample processing
Blood and saliva samples were collected prior to all interven-
tions and throughout the study period. Plasma was stored at
80 C for antibody measurement. At the time of euthanasia, ton-
sils, lymph nodes (LN: axillary, mesenteric, retropharyngeal and
submandibular), and intestinal tissues (colon and ileum) were col-
lected, and mononuclear cell suspensions (MNC) were prepared as
described [34]. Saliva was collected using Weck-Cel sponges (Bea-
ver Visitec), immediately snap frozen, and later eluted as described
At the terminal time point, 2–3 g of fresh stool were added to 0.5%
BSA in 5 ml sterile PBS supplemented with 1/100 protease inhibi-
tor cocktail (Sigma, P8340) and snap-frozen. Fecal extracts were
prepared by vortexing the thawed contents until complete homog-
enization, removing debris by ultracentrifugation (4 C, 10 min),
ﬁltration (0.45 lm), and concentration to 0.5 ml using an Amicon
Ultra-4 50 K centrifugal ﬁlter unit (Millipore).
2.4. SIV-speciﬁc antibodies and immunoglobulin (Ig) measurements
Anti-SIV IgG and IgA antibodies in plasma and fecal extracts,
and salivary IgA were measured by ELISA as described [34]. Brieﬂy,
plates were coated overnight with 100 ng SIVmac251 Env rgp120
(Immune Technology, New York, NY) or 100 ll 1/400 SIVmac239
lysate (Advanced Biotechnologies, Columbia, MD) per well in PBS.
Antibodies against the lysate are termed ‘‘Gag, Pol’’-speciﬁc be-
cause Env protein is undetectable at the dilution used. Total IgA
or IgG in saliva or fecal extracts were measured by capture ELISA
[15,35] using goat anti-monkey IgA (AlphaDiagnostics, San Anto-
nio, TX) or goat anti-monkey IgG (MP Biomedicals), respectively,
to capture Ig. The following day, plates were washed, blocked
and loaded with diluted samples and a monkey serum standard
containing known amounts of Ig, SIV-speciﬁc IgA or SIV-speciﬁc
IgG. After overnight incubation (4 C), the plates were developed
with biotinylated goat anti-monkey IgA or anti-human IgG
antibody (SouthernBiotech, Birmingham, AL), and avidin-labeled
peroxidase (Sigma). The SIV Env or Gag, Pol-speciﬁc IgA or IgG anti-
body concentrations in each secretion were normalized to total IgA
or IgG concentration. The speciﬁc activity (ng IgA or IgG antibody
per lg total IgA or IgG) was deemed signiﬁcant if it was greater
than the mean + 3SD of negative controls.
2.5. Antigen-speciﬁc T cell responses
1  106 blood or tissue MNC were treated with 0.5 lg anti-
CD28 and anti-CD49d (BD Biosciences, San Jose, CA) in 1 ml sup-
plemented RPMI plus (i) no stimulant, (ii) 5 ng/ml PMA/500 ng/
ml Ionomycin (Sigma, St. Louis, MO), (iii) 10 lg SIVmac239 p27
Gag peptide pool, (iv) 10 lg SIVmac239 Env peptide pool (both:
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protein derivative (Tuberculin PPD, Statens Serum Institute,
Copenhagen, Denmark), (vi) 10 ll BCG vaccine (105 CFU; Statens
Serum Institute), (vii) 50 lg Mtb H37Rv recombinant culture ﬁl-
trate protein-10 reference standard (rCFP), (viii) 50 lg Mtb
H37Rv whole strain lysate, or (ix) 25 lg Antigen 85b reference
standard (Ag85b; all from BEI Resources Manassas, VA). Cells were
cultured for 6 h (37 C, 5% CO2) with 1 brefeldin A (eBioscience,
San Diego, CA) treatment after the ﬁrst hour. Cells were stained
using a ﬁxable live/dead discriminator (Invitrogen) and antibodies
against rhesus macaque CD3, CD4, IL-2, TNF-a, IFN-c, (BD Biosci-
ences, San Jose, CA) and IL-17A (eBioscience). When cell counts
permitted, unstimulated MNC suspensions were stained for mark-
ers of T cell memory (CD45RA, CCR7) and mucosal homing
(CD103). All panels included ﬂuorescence-minus-one controls.
Paraformaldehyde-ﬁxed samples were acquired on a LSRII instru-
ment and analyzed using FlowJo software with Boolean gating
(TreeStar, Ashland, OR). Antigen-speciﬁc T cell responses were cor-
rected for background responses in unstimulated controls and are
reported as percentage of CD4+ or CD8+ T cells.
2.6. Statistical analysis
Data were analyzed using Prism (GraphPad, Inc., La Jolla, CA).
Correlations between IgA in various compartments (plasma, saliva,
intestine) were analyzed using the Spearman rank test to deter-
mine the effect of antibody transudation versus mucosal antibody
production. Frequencies of CD103 positive T cell populations were
compared by applying a two-tailed Student’s t-test with Welch’s
correction. P values 60.05 were considered signiﬁcant.3. Results
3.1. TB-speciﬁc immunity after a single prime with attenuated Mtb
We have previously shown that mc26435 induces plasma IgG
antibodies to the mycobacterial antigen PSTS-1, albeit at signiﬁ-
cantly lower levels than the more replication-competent strain
mc26020 [15]. In contrast, independent of replication capacity,
the magnitude and persistence of Mtb-speciﬁc peripheral blood T
cell responses were similar in mc26020 and mc26435 vaccinated
infant macaques (Fig. 1A or B, Table 1). Mtb-speciﬁc T cell re-
sponses consisted primarily of cells producing IL-2, IFN-c, TNF-a
or IL-17 (Fig. 1C, Table 1), but dual and triple polyfunctional T cells
were detected at multiple time points (Fig. 1D). Although only PPD
and Ag85b-speciﬁc responses were consistently evaluated due to
limited infant blood volumes, mc26435 vaccinated animals also
developed rCFP10-speciﬁc CD4+ and CD8+ T cell responses, indicat-
ing that mc26435 elicited responses to human immunodominant
epitopes that are absent in BCG (Fig. 1D). Broad polyfunctional
Mtb-speciﬁc T cell responses were also elicited in multiple tissues
(Fig. 1E). Consistent with the oral route of immunization, Mtb-
speciﬁc T cell responses were induced in tonsils and LN draining
the oropharynx (Table 1), with the highest Mtb-speciﬁc T cell re-
sponses developing in ileum and colon (Table 1).
3.2. SIV-speciﬁc T cell immune responses in peripheral blood and
tissues
A single oral immunization with mc26435 was sufﬁcient to in-
duce SIV Gag-speciﬁc T cell responses by 3 weeks of age
(Fig. 2A), prior to MVA-SIV boosting. SIV Gag-speciﬁc T cell fre-
quencies did not increase after MVA-SIV boosts (Fig. 2B), but dual
and triple cytokine-producing T cells increased in frequency and
diversity (Fig. 2C), suggesting improved quality of SIV Gag re-sponses. In addition, SIV-speciﬁc T cell immunity increased in
breadth through induction of Env-speciﬁc T cells. SIV Gag and
SIV Env-speciﬁc T cell responses were observed at multiple time
points indicative of induction of SIV-speciﬁc T cell memory in
blood and tissues (Table 2).
Consistent with oral priming, frequencies of CD103 positive
central memory (CD3+CD4+CD45RACCR7+, TCM) and effector/
effector memory (CD3+CD4+CD45RA+/CCR7, TE/EM) CD4+ T cell
populations were higher in multiple tissues of vaccinated animals
compared to mock animals, including the ileum (CD4+TE/EM:
p = 0.0326), colon (CD4+TE/EM: p = 0.0032), and the retropharyngeal
LN (CD4+TCM: p = 0.0239) draining the oropharynx (Fig. 3A). Simi-
larly, a higher percentage of ileal CD8+ TCM expressed CD103 com-
pared to mock animals (p = 0.0028). The biological meaning of
decreased CD103+CD8+TE/EM cells in axillary LN is questionable be-
cause CD103 is a mucosal homing marker, and CD103+CD8+TE/EM
frequencies were similar in all other tissues (Fig. 3A). Due to lim-
ited cell numbers, memory and homing markers were only evalu-
ated on total CD4+ and CD8+ T cell populations. However, tissues
with higher CD103+ T cell frequencies generally also had higher
numbers of SIV-speciﬁc T cells. Thus, SIV-speciﬁc T cells were most
pronounced in intestinal tissues (Fig. 3B), but also detectable in at
least one other tissue of each vaccinated animal (Fig. 3C). Re-
sponses were directed to SIV Gag and SIV Env and consisted of sin-
gle and polyfunctional T cells with CD8+T cells being induced at
higher frequencies and in more tissues than SIV-speciﬁc CD4+T
cells (Fig. 3C).3.3. Induction of systemic and mucosal SIV-speciﬁc antibodies
In contrast to SIV-speciﬁc T cell responses, anti-SIV Gag, Pol
plasma IgG antibodies were rarely detected prior to boosting, but
ultimately developed in all animals after the MVA-SIV boosts.
Anti-SIV Gag, Pol- and anti-SIV Env-speciﬁc plasma IgG responses
peaked at week 8 and were maintained at high levels (Fig. 4A or
B). Plasma SIV Env speciﬁc IgA antibodies also peaked by 8 weeks,
but subsequently declined, while SIV Gag-speciﬁc IgA antibodies
showed a more variable pattern (Fig. 4A or B).
Considering the potential importance of mucosal antibodies in
preventing MTCT of HIV by breast-feeding, we measured anti-SIV
Gag, Pol and anti-SIV Env-speciﬁc IgA in mucosal compartments
of vaccinated animals. Even though SIV Gag was a component of
both the mc26435 prime and the MVA-SIV boosts, anti-SIV Gag,
Pol-speciﬁc IgA was present in saliva of only 1 of 8 vaccinated
animals, whereas anti-SIV Env-speciﬁc salivary IgA antibodies
developed in four vaccinees (Fig. 4C). At euthanasia, we detected
anti-SIV Env- or anti-SIV Gag, Pol-speciﬁc IgA and IgG intestinal
antibodies in 4 of 8 and 6 of 8 animals, respectively. One of 8 ani-
mals (#41690) failed to develop SIV-speciﬁc intestinal IgG or IgA
antibodies (Fig. 4D), despite high plasma antibodies to SIV Env.
In fact, plasma anti-Env IgA levels did not correlate with those in
stool (p = 0.9768; R = 0.0238) or in saliva (p = 0.3333;
R = 1.000), suggesting that anti-Env-speciﬁc IgA in the secretions
was derived from local mucosal synthesis rather than passive
serum transudation (data not shown).4. Discussion
Protective immunity against TB is thought to be primarily med-
iated by T cells [36–38], while prevention of HIV infection requires
broadly-neutralizing antibodies [39] and T cell immunity to con-
trol early viral replication should HIV infection occur [24,40].
Towards the long-term goal of developing a pediatric HIV-TB vac-
cine, the main study objective was to provide proof of concept that
a highly attenuated Mtb strain expressing SIV antigens could
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Fig. 1. Mtb-Speciﬁc T cell responses in PBMC. Panels A and B: CD4+ and CD8+ T cytokine responses after in vitro BCG or PPD stimulation of longitudinally collected blood
samples from a representative animal vaccinated with strain mc26020 (panel B) or with strain mc26435 (panel C), respectively. Note, only single-functional responses are
shown. Panel C: polyfunctional T cell responses in a representative animal in longitudinally collected blood samples. Panel D: T cell responses are induced against a number of
Mtb-speciﬁc antigens (PBMC data from a representative animal). Panel E: the percentage of animals with vaccine-induced single and polyfunctional PPD-speciﬁc T cell
responses in tissues. T cells were isolated from selected tissues (tonsil, submandibular LN, ileum, colon and axillary LN) from all animals in group B. Using a gray scale
gradient, the percentage of vaccinated animals that have PPD-speciﬁc cytokine producing T cells in all ﬁve tissues (indicated as ‘5’) is indicated in black, whereas animals
lacking PPD-speciﬁc responses in all ﬁve tissues (indicated as ‘0’) are shown in white. Data are stratiﬁed by CD4+ and CD8⁄ T cells. CFP,Mtb culture ﬁltrate protein; lysate,Mtb
whole cell lysate; BCG, Bacille Calmette–Guérin vaccine strain; Ag85b, antigen 85b.
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Table 1
Mtb-Speciﬁc single cytokine T cell responses.
Tissue Time (wks) PPD Ag85b
IL-2a IFN-c IL-17A TNF-a Animal no.b (%) IL-2 IFN-c IL-17A TNF-a Animal no. (%)
PBMC
CD4+T 3 0.028–0.844 0.014c 0.038–0.050 0.016 6/6 (100) NTd NT NT NT
6 0.014–0.022 0.013 NS 0.021 6/7 (86) 0.168–16.09 NSe NS NS 2/2 (100)
8 0.012–0.084 0.010–0.012 0.039 0.012–0.013 6/8 (75) 0.158–0.239 0.023–0.051 0.037–0.046 1.440–2.220 5/5 (100)
16–18 0.017–0.130 NS 0.061–0.148 0.013 3/8 (38) 0.148–0.373 NS 0.038–0.191 NS 5/8 (63)
CD8+T 3 0.238–0.911 0.033–0.296 NS 0.047–0.307 6/6 (100) NT NT NT NT
6 NS 0.038–0.139 NS 0.041–0.204 4/7 (57) 0.163–15.19 0.493 NS NS 2/2 (100)
8 NS 0.013–0.066 NS 0.048–0.053 6/8 (75) 0.130–0.386 0.121–0.603 0.046–0.137 0.399–1.146 5/5 (100)
16–18 NS 0.025–0.074 0.141 0.053–0.123 5/8 (63) 0.152–0.212 0.043–0.208 0.093 0.148 3/8 (38)
Tonsil
CD4+T 16–18 0.011–0.033 NS 0.158 0.013 3/8 (38) NT NT NT NT
CD8+T 16–18 0.034–0.131 NS NS 0.088 3/8 (38) NT NT NT NT
Subm. LN
CD4+T 16–18 0.085–0.968 NS 0.066–0.081 4.258 4/8 (50) 0.041 0.011 NS 0.022 3/7 (43)
CD8+T 16–18 0.440–0.812 NS 0.136 0.040–0.677 4/8 (50) NS NS NS NS 0/7 (0)
Ileum
CD4+T 16–18 0.043–0.077 0.039–0.044 0.275–0.800 0.057–0.166 4/6 (67) 0.023–0.062 NS 0.597 0.037–0.633 6/7 (86)
CD8+T 16–18 0.294 0.171 0.305 0.080–1.068 4/6 (67) 0.014–0.097 0.020–0.095 0.239–0.298 0.454–1.328 6/7 (86)
Colon
CD4+T 16–18 0.068–0.363 0.020–0.450 0.182–0.320 0.055–0.166 6/8 (75) 0.066–0.591 0.019–0.600 NS 0.025–0.156 7/8 (88)
CD8+T 16–18 0.535 1.360 NS 0.055–0.212 4/8 (50) 0.187–0.525 0.023–1.550 0.204–0.360 0.180–0.259 7/8 (88)
Mes. LN
CD4+T 16–18 NS NS 0.048 0.011–0.166 4/8 (50) NS 0.067 NS NS 1/8 (13)
CD8+T 16–18 NS NS 0.018 0.024–0.097 6/8 (75) 0.021–0.029 0.033 NS 0.125 7/8 (88)
Ax. LN
CD4+T 16–18 0.040 NS NS 0.012 2/8 (25) 0.025 NS NS NS 1/8 (13)
CD8+T 16–18 NS 0.049 NS 0.068–0.138 2/8 (25) NS NS 0.014 0.036–0.080 5/8 (63)
a Shown are the ranges of the percentage of cytokine positive CD4+ or CD8+ T cells.
b Only a single animal had a positive response.
c NT = not tested.
d NS = not signiﬁcant; responses were not different from media only controls.
e Depending on cell numbers, not all animals were tested at all time points for antigen-speciﬁc responses. Shown are the number of responding animals/total animals tested. In parentheses we report the percentages of animals
with positive responses.
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Fig. 2. SIV-speciﬁc peripheral blood T cell responses Panel A: cytokine production following SIV Gag stimulation in peripheral T cells at week 3 for all mc26435-primed
animals in group B. Panel B: CD4+ (left panel) and CD8+ (right panel) T cell cytokine production in response to in vitro SIV Gag stimulation in longitudinally collected blood
samples of a representative animal after vaccination. Panel C: SIV-speciﬁc single, dual and triple positive cytokine responses in peripheral blood CD4+ (left panel) and CD8+
(right panel) T cells at weeks three (post-prime, pre-boost), eight (post-boosts) and 16. Distinct cytokines or combinations thereof are indicated by different colors in the
graph legend.
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Table 2
SIV-speciﬁc single cytokine T cell responses.
Tissue Time (weeks) SIV Gag SIV Env
IL-2 IFN-c IL-17A TNF-a Animal no. (%) IL-2 IFN-c IL-17A TNF-a Animal no. (%)
PBMC
CD4+T 3 0.068 0.043–0.255 0.061–0.109 0.028–0.207 7/8 (88) NT NT NT NT
6 0.040–0.217 NS 0.056–0.072 0.011–0.016 6/8 (75) 0.030 NS 0.081 0.023 3/4 (75)
8 0.175 NS 0.113 NS 2/8 (25) 0.038 NS 0.051 0.014 3/6 (50)
16–18 0.050 NS 0.062–0.136 0.010–0.015 5/8 (63) 0.016–0.096 0.014–0.025 0.045–0.202 0.013–0.019 6/8 (75)
CD8+T 3 0.131–0.181 0.125–1.329 0.077–0.233 0.056–0.281 8/8 (100) NT NT NT NT
6 0.224 0.050–0.100 0.181 0.022–0.096 5/8 (63) NS 0.063 0.069 0.039–0.044 3/4 (75)
8 0.219 0.065 0.129 0.022–0.049 5/8 (63) NS 0.012–0.174 0.041 0.030 4/6 (67)
16–18 0.048–0.062 0.038–0.063 0.104–0.124 0.080 6/8 (75) 0.139 0.018–0.049 0.089–0.240 0.025–0.120 7/8 (88)
Tonsil
CD4+T 16–18 0.167 NS 0.196 NS 3/8 (38) 0.015–0.126 NS 0.155 0.019–0.028 5/5 (100)
CD8+T 16–18 0.013–0.213 0.027–0.027 0.176–0.572 0.095–0.105 6/8 (75) 0.042–0.227 NS 0.412 0.053–0.190 5/5 (100)
Subm. LN
CD4+T 16–18 NS NS NS NS 0/8 (0) 0.011–0.013 NS NS 0.018 3/8 (38)
CD8+T 16–18 0.010–0.018 0.011–0.016 NS NS 4/8 (50) 0.035–0.048 0.012 NS 0.010–0.030 7/8 (88)
Ileum
CD4+T 16–18 0.058–0.174 0.021–0.144 0.165–0.900 0.144–0.396 6/7 (86) 0.0221–0.075 0.024–0.242 0.315–0.395 0.241–0.499 7/7 (100)
CD8+T 16–18 0.023–0.294 0.011–0.077 0.426 0.026–0.878 7/7 (100) 0.064 NS 0.090–1.065 0.032–1.008 7/7 (100)
Colon
CD4+T 16–18 0.333 0.290 0.118 0.029 3/8 (38) 0.228–0.711 0.033–0.920 0.010–0.130 0.011–0.019 6/8 (75)
CD8+T 16–18 0.143–0.625 0.043–1.130 NS 0.069–0.237 4/8 (50) 0.022–0.505 0.015–0.820 0.050–0.161 0.156–0.193 6/8 (75)
Mes. LN
CD4+T 16–18 NS 0.010 0.025–0.464 0.016–0.033 6/8 (75) 0.010 0.014 0.101 0.033 5/8 (63)
CD8+T 16–18 0.022–0.029 NS 0.024–0.568 0.062–0.121 7/8 (88) 0.012–0.048 0.027 0.075 0.049–0.073 6/8 (75)
Ax. LN
CD4+T 16–18 NS NS NS NS 0/8 (0) NS NS NS 0.016 1/8 (13)
CD8+T 16–18 NS 0.052 NS 0.053–0.19 5/5 (100) 0.047–0.062 NS NS 0.073–0.083 3/8 (38)
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A.  Vaccine-enhanced Expression of CD103 by Memory and Effector T Cell Populations
B.  SIV Gag-specific T Cell Responses in Mucosal Tissues
C.  SIV-specific Polyfunctional T Cell Responses in Tissues
SIV Gag SIV Env
Fig. 3. Homing and SIV-speciﬁc T cell responses in tissues. Panel A: animals primed with strain mc26435 and boosted with MVA-SIV (gray bars) have higher percentages of
memory and effector T cells expressing CD103 compared to unvaccinated animals (white bars). Memory and effector/effector memory cells were deﬁned within the CD4+ or
CD8+ T cell populations as CD45RACCR7 (TCM) or CD45RA+/CCR7 (TE/EM), respectively, before measuring CD103 expression. Statistical signiﬁcance using a one-tailed t-test
was calculated using log-transformed values. Shown are mean values ± SEM. Tissues are abbreviated as follows: tonsil (TON), submandibular lymph node (SUB),
retropharyngeal lymph node (RET), ileum (ILE), colon (CO), mesenteric lymph node (MES), axillary lymph node (AX), and PBMC. Panel B: CD4+ (left panel) and CD8+ (right
panel) T cell single cytokine production in response to in vitro SIV Gag stimulation of tissue cell populations. Each bar represents the sum of all single cytokine responses in the
relevant tissue (see legend for cytokine color coding). Shown are data for all animals that were vaccinated orally with strain mc26435 and boosted with MVA-SIV. The three
bars for each animal represent from left to right: colon (C), ileum (I), and tonsil (T). Panel C: the percentage of animals with vaccine-induced single and polyfunctional T cell
responses to SIV Gag (left panel) or SIV Env (right panel). T cells were isolated from tonsil, submandibular LN, retropharyngeal LN, ileum, colon, mesenteric LN, and axillary LN
of all vaccinated animals. Data are stratiﬁed for single and dual cytokine producing CD4+ and CD8⁄ T cells. Using a gray scale gradient, animals with T cells from all seven
tissues producing no cytokine(s) in response to SIV are indicated by ‘0’ (white) and animals with all seven tissues producing cytokine(s) are shown as ‘7’ (black).
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caques. To prevent TB and HIV infections, vaccine-induced memoryresponses need to be elicited and persist at sites of pathogen entry
and replication, i.e., the lung, and the oropharynx and intestinal
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D.  Anti-SIV Gag, Pol and Env IgG and IgA (Intestinal)
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Fig. 4. SIV-speciﬁc plasma and mucosal IgG and IgA antibodies. Panels A and B: anti-SIV Gag, Pol or anti-SIV Env IgG (left graphs) and IgA (right graphs) antibody
development in plasma following oral priming with strain mc26435 plus MVA-SIV boosts. Note that IgG values are represented on a log scale and IgA values are plotted
linearly. Panel C: SIV Gag, Pol (left panel) and Env (right panel) speciﬁc activity for IgA in saliva following priming with strain mc26435 plus MVA-SIV boosts. Panel D: the
speciﬁc activity for intestinally-secreted anti-SIV Gag, Pol (black) and anti-SIV Env (gray) IgA (left) and IgG (right) antibodies following priming with strain mc26435 plus
MVA-SIV boosts. Intestinal antibodies were only measured at the time of euthanasia. One (⁄) or two stars (⁄⁄) above bars indicate that antibody measurements for anti-SIV Env
or anti-SIV Gag, Pol, respectively, exceeded mean background levels ± 3SD.
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oral mc26435 prime/IM MVA-SIV boost regimen could effectively
induce persistent mucosal and systemic dual immune responses.
Indeed, our results show that a single oral immunization with
mc26435 is sufﬁcient to induce broad and persistent Mtb and
SIV-speciﬁc T cell responses in blood and tissues. Mtb-speciﬁc T
cell responses were elicited to multiple TB antigens, including
CFP, a known immunodominant antigen in humans that is absent
in BCG [14]. Although we did not include a BCG control group in
this ﬁrst study, evidence from mouse studies shows that strain
mc26435 is as immunogenic as BCG (manuscript in preparation,
Ranganathan et al.). Furthermore, PPD-speciﬁc CD4+ and CD8+T cell
frequencies in infant macaques after a single oral mc26435 immu-
nization are comparable to PPD-speciﬁc ELISPOT responses (3000–
5000 SPU/106 PBMC or 0.3–0.5% PBMC) elicited by an auxotrophic
recombinant BCG-SIV vaccine and by standard BCG in adult maca-
ques [9]. Some mc26435-vaccinated animals had predominantly
IL-17A-producing Mtb-speciﬁc T cells in tissues. The role of IL-17
in TB is still controversial, but some studies suggest a protective
role of Th17 cells in the lung [38,41–44]. The current study lacked
the analysis of Mtb-speciﬁc lung responses, but future studies will
thoroughly assess the quantity, quality and breadth of the lung re-
sponses to determine the potential of mc26435 vaccination to pro-
tect against TB infection.
SIV-speciﬁc tissue T cell responses were measured in sites
draining the oropharynx, in the intestinal tract as an important
site for vaccine-induced SIV immunity to prevent CD4+ T cell
depletion, and the axillary LN as representative distal site follow-
ing oral priming. SIV-speciﬁc T cell responses were most consis-
tently induced in intestinal tissues and the tonsils. Interestingly,
intestinal tissues and lymph nodes draining the oral cavity also
contained signiﬁcantly higher frequencies of CD103+ memory
CD4+ and CD8+ T cells compared to mock-immunized infants
indicative of mucosal homing. Support for the successful induc-
tion of mucosal immunity was further provided by the presence
of SIV-speciﬁc IgG and IgA antibodies in intestine and mucosal
IgA in saliva. Because the SIV Env immunogen was only present
in the MVA-SIV boosts and because the intestinal antibodies had
speciﬁcity for SIV Env and SIV Gag, Pol antigens, likely both the
mucosal (PO) prime and systemic (IM) boosts contributed to the
development of the intestinal antibody response. The role of IgA
in protection against oral SIV infection remains to be demon-
strated conclusively. In the HIV Thai vaccine trial, systemic HIV
Env-speciﬁc IgA antibodies an increased risk of HIV acquisition
[45]. However, mucosally-induced SIV Env-induced antibodies
persisting at mucosal sites might be important for protection
against oral HIV infection in infants. Passive immunization stud-
ies demonstrated that systemic administration of antiviral IgG,
which transudates into the saliva, could confer protection
against oral infection by high in vitro neutralization and/or AD-
CVI activity [46–48]. Experiments assessing different vaccine-
induced antibody functions will be essential in future studies
[49]. Oral SIV challenge studies will be needed to determine
the relative contribution of SIV-speciﬁc T cell responses, SIV-
speciﬁc salivary and intestinal IgA, and intestinal IgG responses
in preventing or controlling infection.
In conclusion, the results of the current study, in combination
with our previous safety assessment of mc26435 in infant
macaques, provide the basis for future development of
auxotrophic Mtb strains candidates as feasible and safe platform
for a pediatric combination HIV-TB vaccine. Further optimization
of this approach will include the testing a cocktail of attenuated
Mtb strains expressing SIV Env, Gag and Pol and boosting Mtb-
speciﬁc responses. While an attenuated Mtb prime/heterologous
viral boost vaccine strategy may not be sufﬁcient to render
sterilizing immunity, this approach may reduce viral transmis-sion rates or viral loads in infants that do become infected.
Future SIV and Mtb challenge studies will evaluate the efﬁcacy
of this or other combination vaccines, but if successful, they
could confer protection against both HIV and TB during the early
period of life, and potentially through adolescence and into
adulthood.
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